Challenge
In a crowded and competitive CGM market, a leading global diabetes device manufacturer sought to drive early adoption of its next-generation sensor.
The goal: reach HCPs treating uncontrolled Type 2 diabetes patients—especially those already on GLP-1 therapy for 3-6 months, to educate them on the benefits of an advanced CGM sensor.